Literature DB >> 17636445

Application of GnRH antagonist in combination with clomiphene citrate and hMG for patients with exaggerated ovarian response in previous IVF/ICSI cycles.

Yu-Hung Lin1, Kok-Min Seow, Bih-Chwen Hsieh, Lee-Wen Huang, Heng-Ju Chen, Shih-Chia Huang, Chih-Yu Chen, Pei-Hsin Chen, Jiann-Loung Hwang, Chi-Ruey Tzeng.   

Abstract

PURPOSE: To investigate if the combination of clomiphene citrate, hMG, and cetrorelix (CC/hMG/cetrorelix protocol) can be applied to patients who had excessive response to GnRHa long protocol.
METHODS: Fifty patients who coasted and failed to conceive in their first cycles stimulated with GnRHa long protocol were stimulated with CC/hMG/cetrorelix protocol. The peak serum estradiol levels, the need of coasting and prolonged coasting (>/=4 days), and the incidences of OHSS were compared.
RESULTS: The peak estradiol level was significantly lower with CC/hMG/cetrorelix protocol compared to GnRHa long protocol. With CC/hMG/cetrorelix protocol, only four patients (8%) needed coasting and no one coasted >/=4 days. In contrast, in the first cycles, 11 patients (22%) needed coasting >/=4 days. The incidence of moderate OHSS was significantly lower with CC/hMG/cetrorelix protocol.
CONCLUSIONS: The CC/hMG/cetrorelix protocol is an acceptable alternative protocol for patients who had excessive response to GnRHa long protocol.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17636445      PMCID: PMC3454942          DOI: 10.1007/s10815-007-9127-8

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  29 in total

1.  Oocyte and embryo quality after coasting: the experience from oocyte donation.

Authors:  V Isaza; J A García-Velasco; M Aragonés; J Remohí; C Simón; A Pellicer
Journal:  Hum Reprod       Date:  2002-07       Impact factor: 6.918

2.  The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles.

Authors:  Ulun Ulug; Mustafa Bahceci; Halit F Erden; Eliezer Shalev; Izhar Ben-Shlomo
Journal:  Hum Reprod       Date:  2002-02       Impact factor: 6.918

3.  Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).

Authors:  F Olivennes; J Belaisch-Allart; J C Emperaire; H Dechaud; S Alvarez; L Moreau; B Nicollet; J R Zorn; P Bouchard; R Frydman
Journal:  Fertil Steril       Date:  2000-02       Impact factor: 7.329

Review 4.  Preventive attitude of physicians to avoid OHSS in IVF patients.

Authors:  A Delvigne; S Rozenberg
Journal:  Hum Reprod       Date:  2001-12       Impact factor: 6.918

Review 5.  The ovarian hyperstimulation syndrome.

Authors:  J G Whelan; N F Vlahos
Journal:  Fertil Steril       Date:  2000-05       Impact factor: 7.329

6.  A low-dose stimulation protocol using highly purified follicle-stimulating hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotropins.

Authors:  R Marci; A Senn; S Dessole; A Chanson; E Loumaye; P De Grandi; M Germond
Journal:  Fertil Steril       Date:  2001-06       Impact factor: 7.329

Review 7.  Ovarian stimulation and endometrial receptivity.

Authors:  D Valbuena; M Jasper; J Remohí; A Pellicer; C Simón
Journal:  Hum Reprod       Date:  1999-12       Impact factor: 6.918

Review 8.  Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review.

Authors:  Annick Delvigne; Serge Rozenberg
Journal:  Hum Reprod Update       Date:  2002 Nov-Dec       Impact factor: 15.610

9.  Ovarian stimulation by clomiphene citrate and hMG in combination with cetrorelix acetate for ICSI cycles.

Authors:  Jiann-Loung Hwang; Lee-Wen Huang; Bih-Chwen Hsieh; Yieh-Loong Tsai; Shih-Chia Huang; Chin-Yu Chen; Mei-Ling Hsieh; Pei-Hsin Chen; Yu-Hung Lin
Journal:  Hum Reprod       Date:  2003-01       Impact factor: 6.918

10.  Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to 'friendly IVF'?

Authors:  J B Engel; M Ludwig; R Felberbaum; C Albano; P Devroey; K Diedrich
Journal:  Hum Reprod       Date:  2002-08       Impact factor: 6.918

View more
  3 in total

1.  Does the addition of clomiphene citrate or letrazole to gonadotropin treatment enhance the oocyte yield in poor responders undergoing IVF?

Authors:  Vuk P Jovanovic; Daniel H Kort; Michael M Guarnaccia; Mark V Sauer; Rogerio A Lobo
Journal:  J Assist Reprod Genet       Date:  2011-10-12       Impact factor: 3.412

2.  Live Birth after Rescue In vitro Maturation-intracytoplasmic Sperm Injection in Type 1 Diabetes, Polycystic Ovary Syndrome Patient Using Clomiphene-antagonist Protocol.

Authors:  Samundi Sankari; M Elanchezhian; Divya Selvamani; M Nagarajan; D Gopikrishnan
Journal:  J Hum Reprod Sci       Date:  2018 Jan-Mar

3.  ESHRE guideline: ovarian stimulation for IVF/ICSI.

Authors:  The Eshre Guideline Group On Ovarian Stimulation; Ernesto Bosch; Simone Broer; Georg Griesinger; Michael Grynberg; Peter Humaidan; Estratios Kolibianakis; Michal Kunicki; Antonio La Marca; George Lainas; Nathalie Le Clef; Nathalie Massin; Sebastiaan Mastenbroek; Nikolaos Polyzos; Sesh Kamal Sunkara; Tanya Timeva; Mira Töyli; Janos Urbancsek; Nathalie Vermeulen; Frank Broekmans
Journal:  Hum Reprod Open       Date:  2020-05-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.